Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lessons Learned: Medtronic Advises On New Tech Add-On Payment Process

This article was originally published in The Gray Sheet

Executive Summary

Device firms applying for a new technology "add-on" payment should take steps to include Medicare beneficiaries in their clinical trials, according to Medtronic Sofamor Danek Reimbursement Group Director Robert Peterson

You may also be interested in...



First Device Qualifies For Add-On Payment; CMS Retains Proposed Threshold

The device industry's hopes to reduce the Centers for Medicare & Medicaid Services' new technology "add-on" payment threshold are riding on a provision in the House's "Medicare Prescription Drug & Modernization Act" of 2003 (HR 1)

Inpatient Payment Rule Provides No New Tech Add-On Payments For Devices

Medtronic Sofamor Danek's InFuse bone graft/LT-Cage lumbar tapered fusion system does not qualify for a new technology add-on payment under the inpatient prospective payment system (IPPS) fiscal 2003 final rule because the device is FDA-approved only for single-level spinal fusion

Agios’ Phase III Data Move It Closer To First Therapy For Rare Anemia

Strong top-line efficacy in pyruvate kinase deficiency patients who don’t receive regular transfusions looks approvable, analysts say, but Agios will await data in regularly transfused patients.

UsernamePublicRestriction

Register

OM004559

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel